Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 3, 2013Molecular Cancer TherapeuticsOpen Access

Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin

View Full Paper
Ask AI
Bookmark
Share

Authors

KFKatrin FriedbichlerBoehringer Ingelheim (Germany)MHMarco H. HofmannBoehringer Ingelheim (Austria)MKMonika KroezBoehringer Ingelheim (Germany)

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Friedbichler et al. (2013) studied this question.

synapsesocial.com/papers/6a75b6c1dcfefe9676dd8ef0https://doi.org/10.1158/1535-7163.mct-13-0598
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Growth factor receptor interplay and resistance in cancer2006 · 129 citations
  2. 2Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways2007 · 256 citations
  3. 3Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor.1993 · 556 citations
  4. 4Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer2001 · 918 citations
  5. 5Altered Expression of Insulin Receptor Isoforms in Breast Cancer2011 · 61 citations